Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan/HCTZ vs Valsartan/HCTZ in Obese Hypertensive T2DM Patients
NCT00239538Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2003
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, open-label trial of telmisartan in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Changes from baseline in the mean SBP and DBP as measured by ambulatory blood pressure monitoring (ABPM) during the last 6 hours of the 24-hour dosing interval at 10 weeks. Started Jan 2003; status: completed.
02
Drugs
telmisartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00239538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239538.